DelveInsight Business Research LLP

DelveInsight’s “Usher syndrome – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Usher syndrome market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Usher Syndrome Overview

Usher syndrome is a rare genetic disorder primarily characterized by deafness due to an impaired ability of the inner ear and auditory nerves to transmit sensory (sound) input to the brain (sensorineural hearing loss) accompanied by retinitis pigmentosa (RP), a disorder that affects the retina and causes progressive loss of vision. 

It is an autosomal recessive disorder – passing from parents to children – that impacts three major senses in the body: vision, hearing, and balance. It is estimated to affect at least 25,000 people in the United States and over 400,000 worldwide. There are three clinical types of Usher syndrome: Type 1 usually causes profound deafness at birth, vestibular (balance) dysfunction, and progressive vision loss; Type 2 usually causes moderate to severe hearing loss at birth and progressive vision loss; Type 3 usually causes later onset progressive hearing loss and progressive vision loss.

Usher Syndrome Epidemiology Insights 

• According to National Institute on Deafness and Other Communication Disorders (NIDCD), Usher syndrome affects approximately 4 to 17 per 100,000 people and accounts for about 50 % of all hereditary deaf-blindness cases. The condition is thought to account for 3 to 6% of all children who are deaf, and another 3 to 6% of children who are hard-of-hearing.

• According to Orphanet data, the prevalence of Usher syndrome is estimated at 1/30,000. It is by far the most common cause of hereditary, combined deafness-blindness. Type-specific cases include Type 1 (around 40% of cases), Type 2 (around 60% of cases), and Type 3 (< 3% of cases).

• Espino et al. (1998) studied the epidemiology of Usher Syndrome in Valencia and Spain. Otological, ophthalmological, and genetic studies were performed in 89 Usher Syndrome patients from 46 families and subjected to statistical and segregation analysis. 41.6% of them suffered from type I, 46.1% from type II, and 12.3% of the classification remained unclear. The estimated prevalence for the Province of Valencia was 4.2/100,000. There was a notable excess of male-only affected multiplex sibships in the sample that could be attributable to an X-linked inheritance.

• According to Stabej et al. (2011), a total of 188 families were recruited for the study: 47 were diagnosed with USH1 on the basis of having a profound congenital hearing loss on audiometry, absent vestibular function on formal testing and typical RP; 121 were diagnosed with USH2 on the basis of sloping moderately to severe congenital sensorineural hearing loss on audiometry and normal vestibular function on formal testing with typical RP; four were diagnosed with USH3 on the basis of progressive sensorineural hearing loss and typical RP.

 Click here to learn more about the Usher Syndrome Market Landscape

The Report Covers the Usher Syndrome  Epidemiology Segmented by:

• Usher Syndrome prevalent cases 

• Usher Syndrome type specific prevalent cases 

• Usher Syndrome age-specific prevalent cases 

• Usher Syndrome diagnosed cases 

• Usher Syndrome treated cases 

Usher Syndrome Market Outlook

The Usher syndrome market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Usher syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Usher syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Usher syndrome market in 7MM is expected to witness a major change in the study period 2019–2032.

Key Companies Working in the Usher Syndrome Market

• Sanofi Pharmaceuticals 

• Neurotech Pharmaceuticals 

• ProQR Therapeutics 

And many others 

Usher Syndrome Therapies Covered and Analyzed in the Report

• N-acetylcysteine

• Ultevursen

• SAR421869

And many others 

Learn more about the Key Companies and Emerging Therapies in the Usher Syndrome Market

Table of Contents 

1. Key Insights 

2. Usher Syndrome Introduction 

3. Executive Summary of Usher Syndrome     –     

4. Disease Background and Overview

5. Epidemiology and patient population

6. Usher Syndrome Emerging Therapies

7. Usher Syndrome Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Usher Syndrome Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services